A protein called semaphorin-3A (SEMA3A) may be a key player in the early cellular mechanisms that cause fat to accumulate…
Articles by Lindsey Shapiro, PhD
In ongoing proof-of-concept Phase 2a trials, Arbutus BioPharma’s imdusiran is showing an ability to possibly eliminate chronic hepatitis…
High blood levels of the growth differentiation factor 15 (GDF15) protein are associated with an elevated risk of liver cancer…
Bluejay Therapeutics’ investigational antibody therapy BJT-778 appears to safely and effectively lower levels of the hepatitis D virus (HDV)…
Vir Biotechnology’s investigational therapy tobevibart, used alone or in combination with another company candidate called elebsiran, can reduce hepatitis…
Physicians from the GI Alliance, the largest physician-led network of gastroenterologists in the U.S., are now actively prescribing…
About one year of treatment with Livmarli (maralixibat) allows about a third of patients with Alagille syndrome to…
Up to two years of daily treatment with Livmarli (maralixibat) controlled itch and reduced blood levels of bile acids…
Can-Fite BioPharma has been approved to enroll U.S. patients in its ongoing Phase 2b clinical trial of the oral…
Interim analyses of data from Phase 2 clinical trials testing Mirum Pharmaceuticals’ oral therapy candidate volixibat in people with…